I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Bradley Albert Margus net worth and biography

Bradley Margus Biography and Net Worth

Director of Arvinas

Mr. Margus currently serves as Co-Founder and Chief Executive Officer of Cerevance, a venture-backed, clinical-stage drug development company focused on pursuing novel targets for brain diseases. From 2009-2012, as Chief Executive Officer of Envoy Therapeutics, he raised $8 million from investors, employed a unique technology to discover new compounds for brain diseases, and sold the company within three years for $140 million. From 2000 to 2007, Mr. Margus was the Chief Executive Officer of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response.

Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the Boards of Second Genome, Presage Biosciences and the non-profit A-T Children’s Project. Additionally, he serves as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.

Mr. Margus obtained his M.B.A. from Harvard Business School.

What is Bradley Albert Margus' net worth?: The estimated net worth of Bradley Albert Margus is at least $1.10 million as of August 25th, 2021. Mr. Margus owns 59,463 shares of Arvinas stock worth more than $1,098,876 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Margus may own. Learn More about Bradley Albert Margus' net worth.
How do I contact Bradley Albert Margus?: The corporate mailing address for Mr. Margus and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Bradley Albert Margus' contact information.
Has Bradley Albert Margus been buying or selling shares of Arvinas?: Bradley Albert Margus has not been actively trading shares of Arvinas over the course of the past ninety days. Most recently, Bradley Albert Margus sold 20,000 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $85.00, for a transaction totalling $1,700,000.00. Following the completion of the sale, the director now directly owns 59,463 shares of the company's stock, valued at $5,054,355. Learn More on Bradley Albert Margus' trading history.
Who are Arvinas' active insiders?: Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?: In the last year, insiders at the sold shares 3 times. They sold a total of 8,597 shares worth more than $404,488.85. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.
Information on this page was last updated on 2/23/2024.

Bradley Albert Margus Insider Trading History at Arvinas

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2021	Sell	20,000	$85.00	$1,700,000.00	59,463
8/13/2021	Sell	5,828	$90.03	$524,694.84	59,463
8/11/2021	Sell	5,000	$90.03	$450,150.00	59,463
3/18/2020	Sell	40,000	$37.46	$1,498,400.00	59,463
10/1/2018	Buy	40,000	$16.00	$640,000.00

Bradley Albert Margus Buying and Selling Activity at Arvinas

Arvinas Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $18.48

$17.53

$18.70

50 Day Range

MA: $24.83

$17.83

$28.04

2 Week Range

Now: $18.48

$17.37

$53.08

Volume

1,763,635 shs

Average Volume

738,855 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82

I was wrong. Dead wrong.

From Porter & Company | Ad